Search results
13 lut 2023 · In triple-negative breast cancer, the combination of cancer immunotherapy based on PD-1/PD-L1 immune checkpoint inhibitors with chemotherapy was effective both in advanced and early setting...
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
1 lut 2023 · In triple-negative breast cancer, the combination of cancer immunotherapy based on PD-1/PD-L1 immune checkpoint inhibitors with chemotherapy was effective both in advanced and early setting...
1 lut 2022 · Research on immune checkpoint inhibitors (ICIs) has made it possible to identify different molecular subtypes and formulate individualized immunotherapy schedules.
Ongoing clinical trials are investigating immunotherapies in other breast cancer subtypes as well as in early-stage disease, potentially expanding the popu-lation of patients with breast cancer who may benefit from immunotherapy. Approval of anti-PD-(L)1 agents for the treatment of breast cancer is relatively recent and, therefore, clin-
1 wrz 2020 · Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges. Review Article. Published: 01 September 2020. Volume 34, pages 611–623, (2020) Cite this article. Download PDF. Debora de Melo Gagliato, Antonio C. Buzaid, Jose Perez-Garcia & Javier Cortes. 1363 Accesses. 39 Citations. 1 Altmetric. Explore all metrics. Abstract.
Immunotherapy, particularly agents targeting the immunoregulatory PD-1/PD-L1 axis, har-nesses the power of the immune system to treat cancer, with unique potential for a durable treatment effect due to immunologic memory.
